186 related articles for article (PubMed ID: 38277387)
1. Physicians' awareness of medication-related osteonecrosis of the jaw in patients with osteoporosis.
Supanumpar N; Pisarnturakit PP; Charatcharoenwitthaya N; Subbalekha K
PLoS One; 2024; 19(1):e0297500. PubMed ID: 38277387
[TBL] [Abstract][Full Text] [Related]
2. Cooperation between physicians and dentists for osteonecrosis of the jaw: a 2022 Japanese survey.
Taguchi A; Hagino H; Inoue D; Endo N; Society JO
J Bone Miner Metab; 2023 Nov; 41(6):829-837. PubMed ID: 37516668
[TBL] [Abstract][Full Text] [Related]
3. Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis - A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso).
Madeira M; Rocha AC; Moreira CA; Aguiar ÁMM; Maeda SS; Cardoso AS; de Moura Castro CH; D'Alva CB; Silva BCC; Ferraz-de-Souza B; Lazaretti-Castro M; Bandeira F; Torres SR
Arch Endocrinol Metab; 2021 May; 64(6):664-672. PubMed ID: 34033275
[TBL] [Abstract][Full Text] [Related]
4. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
5. Differences in the Knowledge and Experience of Physicians and Dentists About Medication-Related Osteonecrosis of the Jaw in Osteoporotic Patients.
Yamori M; Tamura M; Mikami M; Mori T; Noi M; Machida Y; Koshinuma S; Yamamoto G
Int Dent J; 2021 Aug; 71(4):336-342. PubMed ID: 33518370
[TBL] [Abstract][Full Text] [Related]
6. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
[TBL] [Abstract][Full Text] [Related]
8. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan.
Kunihara T; Tohmori H; Tsukamoto M; Kobayashi M; Okumura T; Teramoto H; Hamasaki T; Yamasaki T; Nakagawa T; Okimoto N; Fujiwara S
Osteoporos Int; 2023 Jun; 34(6):1101-1109. PubMed ID: 37002373
[TBL] [Abstract][Full Text] [Related]
9. Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.
Acharya S; Patil V; Ravindranath V; Kudva A; Nikhil K
J Med Life; 2022 Mar; 15(3):368-373. PubMed ID: 35449990
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan.
Ishimaru M; Ono S; Morita K; Matsui H; Hagiwara Y; Yasunaga H
J Oral Maxillofac Surg; 2022 Apr; 80(4):714-727. PubMed ID: 35033505
[TBL] [Abstract][Full Text] [Related]
11. Medical and Dental Professions' Varying Levels of Awareness Regarding Medication-related Osteonecrosis of the Jaw in Saudi Arabia? A Cross-sectional Study.
Aljohani MH; Aljohani AS; Aljohani RM; Alsharif WK; Nourwali I; Elsayed SA
J Contemp Dent Pract; 2024 Jan; 25(1):62-67. PubMed ID: 38514433
[TBL] [Abstract][Full Text] [Related]
12. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report.
Penoni DC; Canellas JVS; Silami MANC; Sader F; Pimentel GS; Leão ATT
Arch Endocrinol Metab; 2023 May; 67(4):e000612. PubMed ID: 37252700
[TBL] [Abstract][Full Text] [Related]
14. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
15. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
16. [Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies].
Tröltzsch M; Tröltzsch M; Pautke C; Otto S
HNO; 2022 Jul; 70(7):499-507. PubMed ID: 35050392
[TBL] [Abstract][Full Text] [Related]
17. Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Study on the Prevalence of Cutaneous Manifestations and the Primary Care Physician's Role in its Early Diagnosis.
Whitefield S; Ilan MB; Lazarovici TS; Friedlander-Barenboim S; Kassem R; Yarom N
Am J Med; 2024 Mar; 137(3):266-272. PubMed ID: 38042241
[TBL] [Abstract][Full Text] [Related]
18. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
19. Awareness of the risk of developing medication-related osteonecrosis of the jaw among bisphosphonate users.
El-Ma'aita A; Da'as N; Al-Hattab M; Hassona Y; Al-Rabab'ah M; Al-Kayed MA
J Int Med Res; 2020 Sep; 48(9):300060520955066. PubMed ID: 32924697
[TBL] [Abstract][Full Text] [Related]
20. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
